Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $21.00 price objective on the stock. D. Boral Capital’s price target suggests a potential upside of 356.52% from the stock’s current price.

TRVI has been the topic of several other reports. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Thursday, December 12th. HC Wainwright raised their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Stock Down 4.2 %

TRVI stock opened at $4.60 on Monday. The firm has a market capitalization of $353.60 million, a PE ratio of -10.45 and a beta of 0.88. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $5.05. The stock’s 50 day moving average is $4.09 and its 200-day moving average is $3.40.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. raised its position in Trevi Therapeutics by 84.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock worth $26,000 after acquiring an additional 2,894 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Trevi Therapeutics by 2.1% in the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock worth $578,000 after purchasing an additional 2,935 shares during the period. SG Americas Securities LLC raised its holdings in shares of Trevi Therapeutics by 14.5% in the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after purchasing an additional 3,387 shares during the period. Invesco Ltd. lifted its stake in Trevi Therapeutics by 21.2% in the fourth quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock valued at $97,000 after purchasing an additional 4,133 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Trevi Therapeutics by 32.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company’s stock valued at $104,000 after purchasing an additional 6,119 shares during the period. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.